Research portfolio
PH1001 to PH1005
PH1001
- Oncology
Research-stage proposed biosimilar candidate referencing trastuzumab
Directed against the extracellular domain of HER2. Target: HER2.
PH1002
- Neurology
Research-stage proposed biosimilar candidate referencing ocrelizumab
Directed against CD20-expressing B lymphocytes. Target: CD20.
PH1003
- Oncology
Research-stage proposed biosimilar candidate referencing bevacizumab
Designed to bind vascular endothelial growth factor A. Target: VEGF-A.
PH1004
- Hematology/Autoimmune
Research-stage proposed biosimilar candidate referencing rituximab
Directed against the CD20 antigen on B lymphocytes. Target: CD20.
PH1005
- Immunology
Research-stage proposed biosimilar candidate referencing infliximab
Directed against soluble and transmembrane TNF-α. Target: TNF-α.
PH1001-PH1005 are research-stage proposed biosimilar candidates. Biosimilarity, safety, efficacy, approved indications, and interchangeability, where such a designation exists, have not been established for any candidate. No Pharmatree candidate has been approved by any regulatory authority. References to reference medicines, their mechanisms of action, and their authorized indications are provided solely for scientific context and do not imply that any Pharmatree candidate has the same characteristics, clinical profile, or regulatory status.